Highly sensitive measurement of cTnI without a reader: the Xip solution

无需读数仪即可高灵敏度测量 cTnI：Xip 解决方案

• 批准号: 9674520
• 负责人: Rajinder Bhatia
• 金额: $ 56.52万
• 依托单位: SILICON BIODEVICES, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-15 至 2021-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9674520
• 关键词: Accident and Emergency department; Acute myocardial infarction; Adoption; Adult; Affect; Aging; Ambulances; American; Award; Bedside Testings; Biological Assay; Biological Markers; Blood; Calibration; Cardiac; Caring; Cause of Death; Characteristics; Chest Pain; Clinic; Clinical; Clinical Research; Coronary; Coronary Care Units; Data; Decision Making; Deep Vein Thrombosis; Devices; Diagnosis; Diagnostic; Drops; Evaluation; Fingers; Goals; Heart failure; Home environment; Hospitals; Hour; Housing; Human; Immunoassay; Investigation; Laboratories; Laboratory Sensitivity; Liquid substance; Measurement; Measures; Medical center; Modality; Multi-site clinical study; Myocardial Infarction; Nurses; Outcome; Patients; Performance; Phase; Point-of-Care Systems; Pregnancy Tests; Process; Product Labeling; Production; Protocols documentation; Provider; Pulmonary Embolism; Reader; Research Activity; Risk Management; Risk stratification; Sampling; Secure; Sepsis; Silicon; Small Business Innovation Research Grant; Specific qualifier value; Speed; Standardization; Symptoms; System; Technology; Temperature; Testing; Time; Triage; Troponin; United States Centers for Medicare and Medicaid Services; Validation; Variant; Western World; Work; attack victim; base; design; digital; high risk; improved; microchip; nano; point of care; pre-clinical; standard of care; thermal stress; urgent care

Project Summary Acute myocardial infarction (MI) is the biggest killer in the western world and is the cause of death for nearly 500,000 Americans each year. The symptoms of MI can be vague and non- specific and 7 million adults present to hospital Emergency Departments in the US each year with suspected MI. Advances in cardiac biomarkers have had a large impact on the diagnosis, risk stratification and management of suspected MI patients and rapid and sensitive testing of cardiac biomarkers, specifically troponin, has become the cornerstone for diagnostic workup and care of suspected MI patients. Rapid troponin testing can decrease time to appropriate treatment for MI patients and allow for faster MI rule-out, which will help decrease the billions expended annually for the care of non-MI patients in coronary care units. Yet, despite the clear need for sensitive and rapid cardiac troponin measurements to quickly diagnose and manage patients, there is no POC system that can match the analytical performance of contemporary sensitive laboratory systems. This project is intended to develop and commercialize a fully integrated POC immunoassay platform, based on a CMOS microchip, that is as easy to use as an over the counter pregnancy test and as accurate as high sensitivity laboratory tests. In addition to troponin, which is critically important, the system will be able to measure a myriad of other biomarkers for heart failure, pulmonary embolism and deep vein thrombosis, sepsis and other conditions where speed, convenience and in the field measurement of biomarkers is important.

项目总结